Last updated: 2026-09-09 04:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Heartbeam, Inc. (BEAT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0.44, with a market capitalization of $24.05M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.40 to $4.00. This page covers its latest market performance, valuation, price trends and company information.
$24.05M | |
$0.44 | |
$80.92 | |
$0.40 | |
$0.43 | |
253.94K | |
692.43K | |
-- | |
$4.00 | |
$0.40 | |
-- | |
-- |
Heartbeam, Inc. (BEAT) last closed at $0.43 as of 2026-09-08 23:51:00, unchanged from the previous close of $0.43.
During the latest regular trading session, BEAT traded between $0.40 and $80.92, with a volume of 253.94K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Heartbeam, Inc. (BEAT) moved from $0.49 to $0.44, representing a decline of 9.18% ($0.04).
The stock traded between $0.40 and $0.50 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 384.43 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.1%
BEAT is currently trading at $0.44, placing it 1.1% of the way from its 52-week low of $0.40 to its 52-week high of $4.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Heartbeam, Inc. (BEAT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.